Pre-Clinical Research
Filter News
Found 9,460 articles
-
Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines
1/3/2024
Sail Biomedicines, Inc. announced that the Company has received two grants from the Bill & Melinda Gates Foundation to advance Sail’s first-in-category Endless RNA™ platform to develop secreted monoclonal antibodies and vaccines for malaria.
-
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery PlatformBioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study
1/2/2024
Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca.
-
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
1/2/2024
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) today announced new preclinical data on the Company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury.
-
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
1/2/2024
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants.
-
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
12/28/2023
Microbot Medical Inc. announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model.
-
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
12/27/2023
Enveric Biosciences announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results.
-
Now designated as a Tech Hub by the White House, Alabama’s nonprofit Southern Research is winnowing its focus and investing in healthcare solutions.
-
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
12/20/2023
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, reported new data on Namodenoson’s anti-obesity mechanism of action.
-
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
12/20/2023
EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed EpiVax's ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai's robust biologics pipeline.
-
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
12/19/2023
NanOlogy LLC, a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.
-
LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus
12/19/2023
LimmaTech Biologics and AbVacc announced a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7, designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus.
-
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
12/14/2023
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced pharmacodynamic data of an incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill route of administration.
-
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
12/13/2023
Kineta, Inc. announced today the peer-reviewed publication in Frontiers in Immunology of preclinical data highlighting the potential of KVA12123 as a new immunotherapy against poorly immunogenic tumors.
-
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
12/13/2023
Transcenta Holding Limited announces that the preclinical anti-tumor efficacy and safety results of [177Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging.
-
Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models
12/12/2023
Ankyra Therapeutics today announced results from a preclinical study demonstrating potent anti-tumor activity of its lead program ANK-101 were published in the December issue of the Journal of Clinical Investigation Insight (JCI Insight).
-
Transfer RNA’s unique biology could enable a mutation-specific, gene-agnostic—and more cost effective—approach to developing treatments for thousands of rare and ultra-rare diseases.
-
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
12/11/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate.
-
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
12/11/2023
Pasithea Therapeutics Corp. today announced positive preclinical results from two in vivo studies evaluating the anti-tumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.
-
NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting
12/11/2023
NovalGen Ltd, a pioneering clinical stage immunology company, shared promising findings from the NVG-111-101, a First in Human, Phase I clinical study, in an oral presentation at the 65th American Society of Hematology Annual meeting, in San Diego, USA.
-
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
12/10/2023
Vincerx Pharma, Inc. announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.